GeneNews research targets many of the most critical and costly problems currently facing patients, providers and reimbursers of healthcare. We have identified four major disease groups where advanced diagnostics technology can make a fundamental difference:
Novel Diagnostics for a New Revolution in Molecular Oncology
GeneNews’ Sentry products will enable earlier and broader detection of cancer. For example, few adults undergo regular screening for colorectal cancer because traditional screening methods are generally inconvenient, uncomfortable and time-consuming. The development of convenient and accurate blood tests for cancer detection would certainly have a positive impact on public heath.
Molecular diagnostics has been dominated by infectious disease testing. The human genome has been sequenced and high density arrays have been in use for over a decade now generating data on gene expression profiling; real time PCR is entrenched in the molecular diagnostics community. Taking advantage of all of these facts, GeneNews is poised to use its proprietary approaches to generate content for a new class of molecular oncology tests. Once developed, our blood based biomarker diagnostics tests may replace or supplement current technology for conditions in which:
- early testing can lead to prevention or cure
- current diagnostic and staging tests are painful, invasive and/or disliked by patients
- current tests fail to provide information about patient prognosis or outlook
- more patient-friendly tests will encourage more people to be tested
- definitive diagnosis will lead to more appropriate choice of treatment
- early stage identification will reduce suffering, morbidity and health care costs
In short, GeneNews is developing and commercializing tests that generate actionable results for physicians to better manage their patients’ illnesses.